· Clinical research
First patient dosed in Phase 3 liver cancer trial of JS207 and JS007
Junshi announced that the first patient had received treatment in a Phase 3 trial evaluating JS207 with JS007 as a first-line treatment for advanced hepatocellular carcinoma.
The study compares the investigational combination with toripalimab plus bevacizumab. The trial is registered as NCT07823348.
Read the full company release